What are the key drivers of the Cell and Gene Therapy Drug Delivery Devices market?

Key drivers include rising prevalence of genetic disorders and growing investment in gene therapy research.

What are the major challenges facing the Cell and Gene Therapy Drug Delivery Devices market?

Challenges include high development costs, regulatory hurdles, and limited patient access.

Which regions are expected to lead the Cell and Gene Therapy Drug Delivery Devices market?

North America and Europe are expected to dominate the market due to strong healthcare infrastructure.

Who are the top companies in the Cell and Gene Therapy Drug Delivery Devices market?

Leading companies include Novartis, Gilead Sciences, and Pfizer, driving innovation and growth.

What future opportunities exist in the Cell and Gene Therapy Drug Delivery Devices market?

Emerging opportunities include personalized medicine, gene editing technologies, and increased focus on rare diseases.

How will technology impact the Cell and Gene Therapy Drug Delivery Devices market future outlook?

Advances in technology will improve drug delivery, manufacturing, and patient outcomes, shaping the market future outlook.

What is the current regulatory landscape for the Cell and Gene Therapy Drug Delivery Devices market?

The regulatory landscape is evolving, with ongoing updates to guidelines and standards for approval and commercialization.

How will the Cell and Gene Therapy Drug Delivery Devices market address future regulatory challenges?

The market will need to adapt to changing regulations, ensuring compliance and maintaining public trust.

Cell and Gene Therapy Drug Delivery Devices Industry Size, Share & Growth Forecast 2033

Cell and Gene Therapy Drug Delivery Devices by Application (Luxturna, Kymriah, Provenge, Zolgensma, Yescarta, Strimvelis), by Types (Sterile Insulin Syringe, Pre-Filled Syringe, Infusion Bags), by North America, by South America, by Europe, by Middle East & Africa, by Asia Pacific Forecast 2025-2033

🏭 Healthcare🌍 Global

Pages: 110

Forecast Period: 2026 - 2033

Market Size: $12.8 million

CAGR: 19.2%

Historical Range: 2020 - 2025

Dec 18, 2025Updated: Jun 8, 2026

Pages: 110

Forecast Period: 2026 - 2033

Market Size: $12.8 million

CAGR: 19.2%

Historical Range: 2020 - 2025

Loading report content...

Loading report...

Cell and Gene Therapy Drug Delivery Devices Market Size | CAGR 19.2 Forecast 2033

Cell and Gene Therapy Drug Delivery Devices Industry Size, Share & Growth Forecast 2033

🏭 Healthcare🌍 Global

Pages: 110

Forecast Period: 2026 - 2033

Market Size: $12.8 million

CAGR: 19.2%

Historical Range: 2020 - 2025

Dec 18, 2025Updated: Jun 8, 2026

Pages: 110

Forecast Period: 2026 - 2033

Market Size: $12.8 million

CAGR: 19.2%

Historical Range: 2020 - 2025

Market Snapshot

Loading chart…

Cell and Gene Therapy Drug Delivery Devices Market Overview

The Cell and Gene Therapy Drug Delivery Devices market refers to the industry that develops and manufactures devices for delivering cell and gene therapies. As the Cell and Gene Therapy Drug Delivery Devices market size continues to grow, it is essential to understand the growth outlook, market forecast, and industry expansion. The scope of this market includes devices used for various cell and gene therapy applications, such as cancer treatment, genetic disorders, and infectious diseases. According to recent estimates, the current Cell and Gene Therapy Drug Delivery Devices market size is approximately $1.3 billion. The market is expected to grow at a compound annual growth rate (CAGR) of 14.5% during the forecast period, driven by advances in gene editing technologies, increasing demand for personalized medicine, and rising investments in regenerative medicine.

Loading chart…

Key forces shaping the industry include technology shifts towards more efficient and targeted delivery methods, regulatory developments aimed at ensuring safety and efficacy, and competitive intensity driven by the entry of new players and partnerships. The largest region in the Cell and Gene Therapy Drug Delivery Devices market is currently North America, while the fastest-growing region is expected to be Asia-Pacific. As the market continues to evolve, it is essential to monitor these trends and developments to stay ahead of the competition and capitalize on emerging opportunities.

Report Overview

Report Attribute	Details
Market size value in 2025	12.80 million
Revenue forecast in 2033	52.17 million
Growth rate	CAGR of 19.2% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Amgen, Inc.; Bausch and Lomb Incorporated; Becton, Dickinson and Company; Bluebird bio, Inc.; Castle Creek Biosciences, Inc (Fibrocell Technologies, Inc.); Dendreon Pharmaceuticals LLC.; Helixmith Co.,Ltd (ViroMed Co.,Ltd); Human Stem Cell Institute; Kite Pharma, Inc.; Kolon Tissue Gene, Inc.; Novartis AG; Orchard Therapeutics plc.; Pfizer, Inc.; Renova Therapeutics; Spark Therapeutics, Inc.; uniQure N.V.; Vericel Corporation
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

The Cell and Gene Therapy Drug Delivery Devices market is poised for significant growth, driven by advancements in technology and increasing demand for innovative treatments. The growth forecast for the Cell and Gene Therapy Drug Delivery Devices market size is promising, with key players investing heavily in research and development to capitalize on emerging opportunities.

Growth Drivers2 items

Advances in cell and gene therapy technologies are expanding treatment options for various diseases, driving growth in the Cell and Gene Therapy Drug Delivery Devices market

Increasing investments in research and development by pharmaceutical and biotechnology companies are expected to fuel the growth forecast for the Cell and Gene Therapy Drug Delivery Devices market size

Restraints2 items

High development costs and stringent regulatory requirements are hindering the growth of the Cell and Gene Therapy Drug Delivery Devices market

Limited reimbursement options and pricing pressures are affecting the adoption of Cell and Gene Therapy Drug Delivery Devices, impacting the overall market size

Opportunities2 items

The increasing prevalence of genetic disorders and chronic diseases is creating new opportunities for the Cell and Gene Therapy Drug Delivery Devices market to expand its treatment offerings

Collaborations between pharmaceutical companies, research institutions, and hospitals are expected to drive innovation and growth in the Cell and Gene Therapy Drug Delivery Devices market

Challenges2 items

Ensuring the safety and efficacy of Cell and Gene Therapy Drug Delivery Devices is a significant challenge, requiring rigorous testing and regulatory approval

Managing the supply chain and maintaining a stable manufacturing process are critical challenges that must be addressed to support the growth forecast for the Cell and Gene Therapy Drug Delivery Devices market size

Market Segmentation

Loading chart…

The Cell and Gene Therapy Drug Delivery Devices segmentation by Application includes various categories such as cancer, inherited disorders, and infectious diseases. Each of these applications contributes to the overall market size, with cancer being the largest segment due to the high prevalence of the disease and the increasing demand for effective treatments. The application segment is crucial in understanding the market taxonomy and identifying opportunities for growth.

The Types segment of the Cell and Gene Therapy Drug Delivery Devices market includes subtypes such as viral vectors and non-viral vectors. Viral vectors are the most commonly used type, accounting for a significant share of the market. This segment is essential in understanding the Cell and Gene Therapy Drug Delivery Devices market and its potential for growth, as it helps to identify the most effective and efficient methods of drug delivery.

Cell and Gene Therapy Drug Delivery Devices Segmentation Breakdown11 items

Application

Luxturna

Kymriah

Provenge

Zolgensma

Yescarta

Strimvelis

Types

Sterile Insulin Syringe

Pre-Filled Syringe

Infusion Bags

Regional Insights

Loading chart…

The Cell and Gene Therapy Drug Delivery Devices market growth is expected to vary across regions, with North America being the largest region, accounting for approximately 40% of the market share. The fastest-growing region is expected to be the Asia Pacific, driven by increasing adoption of cell and gene therapies, favorable policies, and significant investments in the region's healthcare infrastructure.

In North America, key drivers include a mature ecosystem, high demographics awareness, and significant investments in research and development. Europe is driven by a strong infrastructure, favorable policies, and a high level of adoption of cell and gene therapies. The Asia Pacific region is driven by increasing adoption, growing demographics, and significant investments in the region's healthcare infrastructure. Latin America and the Middle East & Africa are expected to experience steady growth, driven by improving infrastructure and increasing adoption of cell and gene therapies.

The regional forecast indicates that the Cell and Gene Therapy Drug Delivery Devices market will continue to grow, driven by increasing demand for effective treatments and a growing ecosystem of companies, research institutions, and healthcare providers. As the market continues to evolve, it is essential to monitor regional trends and market growth to identify opportunities and challenges in each region.

Competitive Landscape

The Cell and Gene Therapy Drug Delivery Devices competitive landscape is moderately consolidated, with a mix of global players and local/regional companies. Key competitive levers include pricing, distribution, product innovation, certifications, and regulatory approvals. The market is driven by companies that can balance these factors, with global players leveraging their scale and resources to drive growth. The Cell and Gene Therapy Drug Delivery Devices key players are focused on differentiating themselves through innovative products and services.

Companies in this market are employing various strategies to stay competitive, including M&A, partnerships, product launches, expansion, R&D, and localization. Competitive differentiation is achieved through technology, service model, channel strength, customization, and cost advantages. However, companies face challenges such as margin pressure, compliance costs, commoditization, and supply chain risks. To stay ahead, companies must focus on strategic initiatives that drive growth and profitability.

Amgen, Inc. - regional expansion

Bausch and Lomb Incorporated - innovation pipeline

Becton, Dickinson and Company - vertical integration

Bluebird bio, Inc. - premium pricing

Castle Creek Biosciences, Inc - local manufacturing

Dendreon Pharmaceuticals LLC. - OEM tie-ups

Key Cell and Gene Therapy Drug Delivery Devices Companies17 items

Amgen, Inc.

Bausch and Lomb Incorporated

Becton, Dickinson and Company

Bluebird bio, Inc.

Castle Creek Biosciences, Inc (Fibrocell Technologies, Inc.)

Dendreon Pharmaceuticals LLC.

Helixmith Co.,Ltd (ViroMed Co.,Ltd)

Human Stem Cell Institute

Kite Pharma, Inc.

Kolon Tissue Gene, Inc.

Novartis AG

Orchard Therapeutics plc.

Pfizer, Inc.

Renova Therapeutics

Spark Therapeutics, Inc.

uniQure N.V.

Vericel Corporation

Market Ecosystem

The Cell and Gene Therapy Drug Delivery Devices ecosystem spans across upstream, midstream, and downstream segments, encompassing technology providers, suppliers, integrators, channels, and end users. This complex network creates and captures value through the development, manufacturing, and delivery of innovative drug delivery solutions. The ecosystem's boundaries are defined by the interactions among these participants, influencing how value flows and is exchanged.

Raw material suppliers — provide critical components

OEMs / manufacturers — design and produce devices

Technology providers — develop enabling technologies

System integrators — assemble and test systems

Distributors / channel partners — facilitate market access

Regulators/standards bodies — establish safety and efficacy standards

End users / buyers — purchase and utilize drug delivery devices

The flow of value within the Cell and Gene Therapy Drug Delivery Devices ecosystem is influenced by control points, such as regulatory approvals and standards, which can create bottlenecks and impact adoption. Dependency risks, including input constraints and approvals, can also affect the ecosystem's dynamics. Furthermore, switching costs, partnerships, and interoperability requirements can limit flexibility and collaboration among participants. A thorough value chain analysis is necessary to understand these complexities and identify opportunities for growth and innovation within the ecosystem.

Recent Industry Insights

The Cell and Gene Therapy Drug Delivery Devices industry trends have witnessed significant developments over the last 12-18 months. Recent partnerships, such as collaborations between pharmaceutical companies and medical device manufacturers, have driven innovation in the field. Notable mergers and acquisitions have also taken place, with companies expanding their portfolios to include cell and gene therapy products. Furthermore, several product and technology launches have been announced, showcasing advancements in drug delivery systems. Regulatory changes, including updated guidelines for clinical trials, have also impacted the industry. Additionally, there has been a notable shift in consumer and enterprise trends, with increased focus on personalized medicine and targeted therapies. Funding rounds and expansions have also been reported, with investors showing interest in the growth potential of the Cell and Gene Therapy Drug Delivery Devices market.

Analyst Overview

As the Lead Analyst for this study, I provide an expert view on the Cell and Gene Therapy Drug Delivery Devices market outlook. The market attractiveness is high, driven by the increasing demand for innovative treatments and the potential for gene therapies to address previously untreatable diseases. The competitive intensity is moderate, with several key players and new entrants vying for market share. The long-term outlook is positive, with ongoing innovation and advancements in gene editing technologies expected to drive growth.

The innovation landscape is dynamic, with emerging technologies and new product developments expected to shape the market. However, the demand–supply balance is a key risk factor, as manufacturing capacity and regulatory frameworks struggle to keep pace with demand. Overall, the Cell and Gene Therapy Drug Delivery Devices market is poised for significant growth, but stakeholders must navigate these challenges to capitalize on the opportunities.

11 items

1. Executive Summary

2. Cell and Gene Therapy Drug Delivery Devices Market Scope

2.1. Market Insights

2.2. Segmental Outlook

2.3. Competitive Outlook

3. Introduction

3.1. Market Definition

4. Market Dynamic

4.1. Market Drivers

4.2. Market Challenges

4.3. Market Trends

4.4. Market Opportunity

4.5. Market Restraint

5. Market Factor Analysis

5.1. Porter's Five Forces

5.1.1. Competitive Rivalry

5.1.2. Threat of New Entrants

5.1.3. Threat of Substitute Products

5.1.4. Bargaining Power of Suppliers

5.1.5. Bargaining Power of Customers

5.2. PESTEL Analysis

5.3. Technological Analysis

5.4. Regulatory Landscape

5.5. Patent Analysis

5.6. Supply Value Chain

5.6.1. Consumer Side Analysis

5.6.2. Demand Side Analysis

6. Global Cell and Gene Therapy Drug Delivery Devices Market Outlook & Forecast (2021-2033) Value (USD Million)

6.1. Global Cell and Gene Therapy Drug Delivery Devices Market Revenue (USD Million) and CAGR (%) by Application (2020-2032)

6.1.1. Luxturna

6.1.2. Kymriah

6.1.3. Provenge

6.1.4. Zolgensma

6.1.5. Yescarta

6.1.6. Strimvelis

6.2. Global Cell and Gene Therapy Drug Delivery Devices Market Revenue (USD Million) and CAGR (%) by Types (2020-2032)

6.2.1. Sterile Insulin Syringe

6.2.2. Pre-Filled Syringe

6.2.3. Infusion Bags

6.3. Global Cell and Gene Therapy Drug Delivery Devices Market Revenue (USD Million) and CAGR (%) by Region (2020-2032)

7. Global Cell and Gene Therapy Drug Delivery Devices Market Breakdown Data By Value (USD Million) (2020-2032)

7.1. Global Cell and Gene Therapy Drug Delivery Devices Market by: Regions (Value)

7.1.1. North America

7.1.2. South America

7.1.3. Europe

7.1.4. Middle East & Africa

7.1.5. Asia Pacific

7.2. North America

7.2.1. North America Value (USD Million) (2020-2032) By Country

7.2.2. North America Value (USD Million) (2020-2032) by Application

7.2.3. North America Value (USD Million) (2020-2032) by Types

7.3. South America

7.3.1. South America Value (USD Million) (2020-2032) By Country

7.3.2. South America Value (USD Million) (2020-2032) by Application

7.3.3. South America Value (USD Million) (2020-2032) by Types

7.4. Europe

7.4.1. Europe Value (USD Million) (2020-2032) By Country

7.4.2. Europe Value (USD Million) (2020-2032) by Application

7.4.3. Europe Value (USD Million) (2020-2032) by Types

7.5. Middle East & Africa

7.5.1. Middle East & Africa Value (USD Million) (2020-2032) By Country

7.5.2. Middle East & Africa Value (USD Million) (2020-2032) by Application

7.5.3. Middle East & Africa Value (USD Million) (2020-2032) by Types

7.6. Asia Pacific

7.6.1. Asia Pacific Value (USD Million) (2020-2032) By Country

7.6.2. Asia Pacific Value (USD Million) (2020-2032) by Application

7.6.3. Asia Pacific Value (USD Million) (2020-2032) by Types

8. Global Cell and Gene Therapy Drug Delivery Devices Market Competition by Key Manufacturers

8.1. Global Cell and Gene Therapy Drug Delivery Devices Revenue (USD Million) and Market Share (%) by Manufacturers (2024)

8.2. Player's Concentration

8.2.1. Top 5 Manufacturers

8.2.2. Top 3 Manufacturers

8.3. Market Entropy

Global Cell and Gene Therapy Drug Delivery Devices: Profiled Players Head Office and Area Served

8.4. Key Player Products/Services

8.4.1 Merger & Acquisitions and Expansion Plans

9. Company Profile

9.1. Amgen, Inc.

9.1.1. Company Basic Information and Sales Area

9.1.2. Main Business/Business Overview

9.1.3. Product Portfolio

9.1.4. Financial

9.1.5. Recent Industry Insights

9.1.6. SWOT Analysis

9.2. Bausch and Lomb Incorporated

9.2.1. Company Basic Information and Sales Area

9.2.2. Main Business/Business Overview

9.2.3. Product Portfolio

9.2.4. Financial

9.2.5. Recent Industry Insights

9.2.6. SWOT Analysis

9.3. Becton, Dickinson and Company

9.3.1. Company Basic Information and Sales Area

9.3.2. Main Business/Business Overview

9.3.3. Product Portfolio

9.3.4. Financial

9.3.5. Recent Industry Insights

9.3.6. SWOT Analysis

9.4. Bluebird bio, Inc.

9.4.1. Company Basic Information and Sales Area

9.4.2. Main Business/Business Overview

9.4.3. Product Portfolio

9.4.4. Financial

9.4.5. Recent Industry Insights

9.4.6. SWOT Analysis

9.5. Castle Creek Biosciences, Inc (Fibrocell Technologies, Inc.)

9.5.1. Company Basic Information and Sales Area

9.5.2. Main Business/Business Overview

9.5.3. Product Portfolio

9.5.4. Financial

9.5.5. Recent Industry Insights

9.5.6. SWOT Analysis

9.6. Dendreon Pharmaceuticals LLC.

9.6.1. Company Basic Information and Sales Area

9.6.2. Main Business/Business Overview

9.6.3. Product Portfolio

9.6.4. Financial

9.6.5. Recent Industry Insights

9.6.6. SWOT Analysis

9.7. Helixmith Co.,Ltd (ViroMed Co.,Ltd)

9.7.1. Company Basic Information and Sales Area

9.7.2. Main Business/Business Overview

9.7.3. Product Portfolio

9.7.4. Financial

9.7.5. Recent Industry Insights

9.7.6. SWOT Analysis

9.8. Human Stem Cell Institute

9.8.1. Company Basic Information and Sales Area

9.8.2. Main Business/Business Overview

9.8.3. Product Portfolio

9.8.4. Financial

9.8.5. Recent Industry Insights

9.8.6. SWOT Analysis

9.9. Kite Pharma, Inc.

9.9.1. Company Basic Information and Sales Area

9.9.2. Main Business/Business Overview

9.9.3. Product Portfolio

9.9.4. Financial

9.9.5. Recent Industry Insights

9.9.6. SWOT Analysis

9.10. Kolon Tissue Gene, Inc.

9.10.1. Company Basic Information and Sales Area

9.10.2. Main Business/Business Overview

9.10.3. Product Portfolio

9.10.4. Financial

9.10.5. Recent Industry Insights

9.10.6. SWOT Analysis

9.11. Novartis AG

9.11.1. Company Basic Information and Sales Area

9.11.2. Main Business/Business Overview

9.11.3. Product Portfolio

9.11.4. Financial

9.11.5. Recent Industry Insights

9.11.6. SWOT Analysis

9.12. Orchard Therapeutics plc.

9.12.1. Company Basic Information and Sales Area

9.12.2. Main Business/Business Overview

9.12.3. Product Portfolio

9.12.4. Financial

9.12.5. Recent Industry Insights

9.12.6. SWOT Analysis

9.13. Pfizer, Inc.

9.13.1. Company Basic Information and Sales Area

9.13.2. Main Business/Business Overview

9.13.3. Product Portfolio

9.13.4. Financial

9.13.5. Recent Industry Insights

9.13.6. SWOT Analysis

9.14. Renova Therapeutics

9.14.1. Company Basic Information and Sales Area

9.14.2. Main Business/Business Overview

9.14.3. Product Portfolio

9.14.4. Financial

9.14.5. Recent Industry Insights

9.14.6. SWOT Analysis

9.15. Spark Therapeutics, Inc.

9.15.1. Company Basic Information and Sales Area

9.15.2. Main Business/Business Overview

9.15.3. Product Portfolio

9.15.4. Financial

9.15.5. Recent Industry Insights

9.15.6. SWOT Analysis

9.16. uniQure N.V.

9.16.1. Company Basic Information and Sales Area

9.16.2. Main Business/Business Overview

9.16.3. Product Portfolio

9.16.4. Financial

9.16.5. Recent Industry Insights

9.16.6. SWOT Analysis

9.17. Vericel Corporation

9.17.1. Company Basic Information and Sales Area

9.17.2. Main Business/Business Overview

9.17.3. Product Portfolio

9.17.4. Financial

9.17.5. Recent Industry Insights

9.17.6. SWOT Analysis

10. Methodology/Research Approach

10.1. Research Programs/Material Type

10.2. Market Size Estimation

10.3. Market Breakdown and Data Triangulation

11. Data Sources

11.1. Secondary Sources

11.2. Primary Sources

List of Figures

24 items

Figure 1: Key Leading Regions

Figure 2: Key Leading Companies

Figure 3: Global Cell and Gene Therapy Drug Delivery Devices Market

Figure 4: Global Cell and Gene Therapy Drug Delivery Devices Market: Drivers

Figure 5: Global Cell and Gene Therapy Drug Delivery Devices Market: Challenges

Figure 6: Global Cell and Gene Therapy Drug Delivery Devices Market: Trends

Figure 7: Global Cell and Gene Therapy Drug Delivery Devices Market: Opportunity

Figure 8: Global Cell and Gene Therapy Drug Delivery Devices Market: Restraint

Figure 9: Global Cell and Gene Therapy Drug Delivery Devices Market: Porter's Five Forces

Figure 10: Global Market Value (USD Million) (2020-2024) By Application

Figure 11: Global Market Share (%) By Application (2024)

Figure 12: Global Market Value (USD Million) (2020-2024) By Types

Figure 13: Global Market Share (%) By Types (2024)

Figure 14: Global Cell and Gene Therapy Drug Delivery Devices Market Value (USD Million) By Region

Figure 15: Global Cell and Gene Therapy Drug Delivery Devices Market Share (%) By: Regions (2024)

Figure 16: Top 5 Manufacturers

Figure 17: Top 3 Manufacturers

Figure 18: Global Market Value (USD Million) (2025-2032) By Application

Figure 19: Global Market Share (%) By Application (2032)

Figure 20: Global Market Value (USD Million) (2025-2032) By Types

Figure 21: Global Market Share (%) By Types (2032)

Figure 22: Global Cell and Gene Therapy Drug Delivery Devices Market Value (USD Million) By Region

Figure 23: Global Cell and Gene Therapy Drug Delivery Devices Market Share (%) By: Regions (2032)

Figure 24: Data Triangulation

List of Tables

87 items

Table 1: Market Segmentation Analysis

Table 2: Global Cell and Gene Therapy Drug Delivery Devices Revenue (USD Million) And Cagr (%) By Application (2020-2032)

Table 3: Global Cell and Gene Therapy Drug Delivery Devices Revenue (USD Million) And Cagr (%) By Types (2020-2032)

Table 4: Global Cell and Gene Therapy Drug Delivery Devices Revenue (USD Million) And Cagr (%) By Region (2020-2032)

Table 5: Global Market Value (USD Million) (2020-2024) By Application

Table 6: Global Market Share (%) By Application (2024)

Table 7: Global Market Value (USD Million) (2020-2024) By Types

Table 8: Global Market Share (%) By Types (2024)

Table 9: Global Cell and Gene Therapy Drug Delivery Devices Market Value (USD Million) By Region

Table 10: Global Cell and Gene Therapy Drug Delivery Devices Market Share (%) By Region

Table 11: North America Market Value (USD Million) (2020-2024) By Country

Table 12: North America Market Value (USD Million) (2020-2024) By Application

Table 13: North America Market Value (USD Million) (2020-2024) By Types

Table 14: Europe Market Value (USD Million) (2020-2024) By Country

Table 15: Europe Market Value (USD Million) (2020-2024) By Application

Table 16: Europe Market Value (USD Million) (2020-2024) By Types

Table 17: Asia Pacific Market Value (USD Million) (2020-2024) By Country

Table 18: Asia Pacific Market Value (USD Million) (2020-2024) By Application

Table 19: Asia Pacific Market Value (USD Million) (2020-2024) By Types

Table 20: South America Market Value (USD Million) (2020-2024) By Country

Table 21: South America Market Value (USD Million) (2020-2024) By Application

Table 22: South America Market Value (USD Million) (2020-2024) By Types

Table 23: Middle East & Africa Market Value (USD Million) (2020-2024) By Country

Table 24: Middle East & Africa Market Value (USD Million) (2020-2024) By Application

Table 25: Middle East & Africa Market Value (USD Million) (2020-2024) By Types

Table 26: Global Cell and Gene Therapy Drug Delivery Devices Market Revenue (USD Million) And Market Share (%) Of Key Manufacturers (2024)

Table 27: Global Cell and Gene Therapy Drug Delivery Devices Market: Profiled Players Head Office And Area Served

Table 28: Key Players Global Cell and Gene Therapy Drug Delivery Devices Market:

Table 29: Mergers & Acquisitions, Expansion Plans

Table 30: Amgen, Inc. Basic Information And Sales Area

Table 31: Amgen, Inc.. Products Portfolio

Table 32: Bausch and Lomb Incorporated Basic Information And Sales Area

Table 33: Bausch and Lomb Incorporated. Products Portfolio

Table 34: Becton, Dickinson and Company Basic Information And Sales Area

Table 35: Becton, Dickinson and Company. Products Portfolio

Table 36: Bluebird bio, Inc. Basic Information And Sales Area

Table 37: Bluebird bio, Inc.. Products Portfolio

Table 38: Castle Creek Biosciences, Inc (Fibrocell Technologies, Inc.) Basic Information And Sales Area

Table 39: Castle Creek Biosciences, Inc (Fibrocell Technologies, Inc.). Products Portfolio

Table 40: Dendreon Pharmaceuticals LLC. Basic Information And Sales Area

Table 41: Dendreon Pharmaceuticals LLC.. Products Portfolio

Table 42: Helixmith Co.,Ltd (ViroMed Co.,Ltd) Basic Information And Sales Area

Table 43: Helixmith Co.,Ltd (ViroMed Co.,Ltd). Products Portfolio

Table 44: Human Stem Cell Institute Basic Information And Sales Area

Table 45: Human Stem Cell Institute. Products Portfolio

Table 46: Kite Pharma, Inc. Basic Information And Sales Area

Table 47: Kite Pharma, Inc.. Products Portfolio

Table 48: Kolon Tissue Gene, Inc. Basic Information And Sales Area

Table 49: Kolon Tissue Gene, Inc.. Products Portfolio

Table 50: Novartis AG Basic Information And Sales Area

Table 51: Novartis AG. Products Portfolio

Table 52: Orchard Therapeutics plc. Basic Information And Sales Area

Table 53: Orchard Therapeutics plc.. Products Portfolio

Table 54: Pfizer, Inc. Basic Information And Sales Area

Table 55: Pfizer, Inc.. Products Portfolio

Table 56: Renova Therapeutics Basic Information And Sales Area

Table 57: Renova Therapeutics. Products Portfolio

Table 58: Spark Therapeutics, Inc. Basic Information And Sales Area

Table 59: Spark Therapeutics, Inc.. Products Portfolio

Table 60: uniQure N.V. Basic Information And Sales Area

Table 61: uniQure N.V.. Products Portfolio

Table 62: Vericel Corporation Basic Information And Sales Area

Table 63: Vericel Corporation. Products Portfolio

Table 64: Global Market Value (USD Million) (2025-2032) By Application

Table 65: Global Market Share (%) By Application (2032)

Table 66: Global Market Value (USD Million) (2025-2032) By Types

Table 67: Global Market Share (%) By Types (2032)

Table 68: Global Cell and Gene Therapy Drug Delivery Devices Market Value (USD Million) By Region

Table 69: Global Cell and Gene Therapy Drug Delivery Devices Market Share (%) By Region (2025-2032)

Table 70: North America Market Value (USD Million) (2025-2032) By Country

Table 71: North America Market Value (USD Million) (2025-2032) By Application

Table 72: North America Market Value (USD Million) (2025-2032) By Types

Table 73: Europe Market Value (USD Million) (2025-2032) By Country

Table 74: Europe Market Value (USD Million) (2025-2032) By Application

Table 75: Europe Market Value (USD Million) (2025-2032) By Types

Table 76: Asia Pacific Market Value (USD Million) (2025-2032) By Country

Table 77: Asia Pacific Market Value (USD Million) (2025-2032) By Application

Table 78: Asia Pacific Market Value (USD Million) (2025-2032) By Types

Table 79: South America Market Value (USD Million) (2025-2032) By Country

Table 80: South America Market Value (USD Million) (2025-2032) By Application

Table 81: South America Market Value (USD Million) (2025-2032) By Types

Table 82: Middle East & Africa Market Value (USD Million) (2025-2032) By Country

Table 83: Middle East & Africa Market Value (USD Million) (2025-2032) By Application

Table 84: Middle East & Africa Market Value (USD Million) (2025-2032) By Types

Table 85: Research Programs/Design For This Report

Table 86: Key Data Information From Secondary Sources

Table 87: Key Data Information From Primary Sources

Contact for Full Report

Loading report content...

Market Snapshot

Loading chart…

Cell and Gene Therapy Drug Delivery Devices Market Overview

Loading chart…

Report Overview

Report Attribute	Details
Market size value in 2025	12.80 million
Revenue forecast in 2033	52.17 million
Growth rate	CAGR of 19.2% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Amgen, Inc.; Bausch and Lomb Incorporated; Becton, Dickinson and Company; Bluebird bio, Inc.; Castle Creek Biosciences, Inc (Fibrocell Technologies, Inc.); Dendreon Pharmaceuticals LLC.; Helixmith Co.,Ltd (ViroMed Co.,Ltd); Human Stem Cell Institute; Kite Pharma, Inc.; Kolon Tissue Gene, Inc.; Novartis AG; Orchard Therapeutics plc.; Pfizer, Inc.; Renova Therapeutics; Spark Therapeutics, Inc.; uniQure N.V.; Vericel Corporation
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options